HC Wainwright Reiterates “Buy” Rating for Celcuity (NASDAQ:CELC)

Celcuity (NASDAQ:CELC)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $27.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 110.77% from the stock’s current price.

CELC has been the subject of a number of other research reports. Leerink Partners began coverage on shares of Celcuity in a report on Monday, July 22nd. They set an “outperform” rating and a $29.00 price objective for the company. Leerink Partnrs raised shares of Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. Lifesci Capital initiated coverage on Celcuity in a report on Monday, August 26th. They issued an “outperform” rating and a $27.00 price target for the company. Stifel Nicolaus raised their price objective on Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $23.00 target price on shares of Celcuity in a report on Friday. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $29.17.

Celcuity Trading Down 9.2 %

NASDAQ CELC traded down $1.30 during trading hours on Friday, hitting $12.81. 604,977 shares of the company were exchanged, compared to its average volume of 278,299. The stock has a market cap of $474.35 million, a PE ratio of -4.68 and a beta of 0.76. Celcuity has a 52 week low of $11.51 and a 52 week high of $22.19. The stock has a 50-day moving average price of $15.23 and a 200 day moving average price of $16.07. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.54.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.09. During the same quarter in the previous year, the firm earned ($0.66) EPS. Analysts forecast that Celcuity will post -2.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Celcuity

Institutional investors have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP lifted its position in shares of Celcuity by 189.9% during the first quarter. Baker BROS. Advisors LP now owns 1,552,478 shares of the company’s stock valued at $33,534,000 after buying an additional 1,017,000 shares during the last quarter. Samlyn Capital LLC raised its stake in shares of Celcuity by 92.4% during the 2nd quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock worth $21,735,000 after acquiring an additional 637,190 shares in the last quarter. State Street Corp lifted its position in Celcuity by 152.2% during the third quarter. State Street Corp now owns 1,107,415 shares of the company’s stock valued at $16,512,000 after acquiring an additional 668,318 shares during the last quarter. Braidwell LP boosted its stake in Celcuity by 71.2% in the third quarter. Braidwell LP now owns 884,306 shares of the company’s stock valued at $13,185,000 after acquiring an additional 367,663 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Celcuity by 1.0% in the first quarter. Vanguard Group Inc. now owns 828,597 shares of the company’s stock valued at $17,898,000 after acquiring an additional 7,821 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.